Product Description
Pyridoxine is a vitamin and a medication used to treat vitamin B6 deficiency and the management of nausea and vomiting during pregnancy. It is also used in vitamin B6 dependency syndromes and controversially used in some other disorders. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32491368/)
Mechanisms of Action: Protein Metabolizer,Carbohydrate Metabolizer,Fatty Acid Metabolizer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Vitamin D Deficiency | Vitamin D Deficiency | Vitamin D Deficiency
Known Adverse Events: Diplopia | Dizziness | Headache | Erythema | Pruritus | Anaphylaxis | Angioedema | Urticaria | Edema
Company: Duchesnay
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Italy, Russia, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Leiomyoma|Morning Sickness|Myofibroma
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Bonjesta-PED-301 | P3 |
Recruiting |
Morning Sickness |
2027-12-01 |
51% |
| Bonjesta-PED-301 | P3 |
Recruiting |
Morning Sickness |
2027-12-01 |
51% |
| DELPHYS PLUS | P3 |
Recruiting |
Leiomyoma|Myofibroma |
2025-07-01 |
66% |
| DELPHYS PLUS | P3 |
Recruiting |
Leiomyoma|Myofibroma |
2025-07-01 |
66% |
| DELPHYS PLUS | P3 |
Recruiting |
Leiomyoma|Myofibroma |
2025-07-01 |
66% |
| DELPHYS PLUS | P3 |
Recruiting |
Leiomyoma|Myofibroma |
2025-07-01 |
66% |
| DIP-05-02-2023 | P1 |
Completed |
Healthy Volunteers |
2024-05-02 |
28% |
| DIP-05-02-2023 | P1 |
Completed |
Healthy Volunteers |
2024-05-02 |
28% |